Inactivation of DNA repair—prospects for boosting cancer immune surveillance
Abstract The emergence of drug resistance depends on the ability of the genome of cancer cells to constantly mutate and evolve under selective pressures. The generation of new mutations is accelerated when genes involved in DNA repair pathways are altered. Notably, although the emergence of new muta...
Main Authors: | Anna Truini, Giovanni Germano, Alberto Bardelli |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Genome Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13073-018-0603-9 |
Similar Items
-
Cancer neoantigen: Boosting immunotherapy
by: Peijia Xu, et al.
Published: (2020-11-01) -
Diverse immune response of DNA damage repair-deficient tumors
by: Tao Qing, et al.
Published: (2021-05-01) -
Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
by: Peipei Wang, et al.
Published: (2021-04-01) -
Possible Biomarkers for Cancer Immunotherapy
by: Takehiro Otoshi, et al.
Published: (2019-07-01) -
HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
by: Yingxue Ren, et al.
Published: (2020-01-01)